Institute for International Research

Key Objectives of the Immunogenicity Studies for Biotherapeutics Conference

• Learn to validate ligand binding assays used for the detection of host antibodies against biotechnology product
• Determine how to develop cellbased assays for detection anti drug neutralizing assays
• Learn to develop and validate drug tolerant ELISA for determination of antibodies to a human therapeutic antibody
• Compare Enzyme-linked, Electrochemiluminescent Immunoassays and Surface Plasmon Resonance as tools in immunogenicity studies
• Learn to develop screening assays for a antibodies and protein/peptide therapeutics
• Understand the current pre-clinical de-immunization strategies in Europe
• Techniques to improve immunoassay tolerance to interfering substances
• Lessons learned from selection of ELISA formats for measuring immunogenicity of a therapeutic protein in preclinical and clinical trials
• Statistical recommendations on immunogenicity method performance characteristics
• Hear how to overcome the challenges of sample-matrix interference in t-cell epitope predictive methods for t-cell epitope discovery techniques

This conference will also be of interest to CROs with Immunogenicity services,Assay technology providers and consulting services to the Pharmaceutical and Biotechnology industry.